NextCure (NXTC) Insider John Houston Buys 2,340 Shares
NextCure Inc insider John Houston added 2,340 shares of the clinical-stage biotech firm in a round of transactions on June 18, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
John Houston bought 2,340 shares of NextCure, Inc. ($NXTC) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NXTC is down 18.3% after 1 week, up 167.3% after 1 month and up 208.9% to date (from the $2.02 close on Jun 18, 2026).
NXTC
NextCure, Inc.
Key Points
- NextCure Inc insider John Houston picked up 2,340 shares of NXTC on June 18, 2026.
- The purchase coincided with coordinated buys from several other insiders including David Kabakoff, Stephen Webster, Elaine Jones, and Borgman Anne Elizabeth.
- NextCure trades at $1.75 per share, sitting well below its 50-day moving average of $6.15 as the clinical-stage biotech advances its oncology and immunology pipeline.
Get $NXTC trade alerts by text
We text you when insiders, Congress or big funds trade $NXTC. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated NextCure, Inc. alert may contain errors. Disclosures
John Houston Adds to NextCure, Inc. NXTC Stake
NextCure, Inc. insider John Houston acquired 2,340 shares of the company on June 18, 2026. The transaction added to the clinical-stage biopharmaceutical firm's recent insider activity, following a coordinated round of purchases by several other company insiders on the same date.
More Insiders Step Up Stock Purchases
On June 18, 2026, multiple insiders joined in the buying activity alongside John Houston. David Kabakoff purchased 3,510 shares, while Stephen Webster, Elaine Jones, and Borgman Anne Elizabeth each picked up 2,340 shares. None of these transactions were carried out under pre-arranged Rule 10b5-1 trading plans.
NextCure Stock Price and Market Standing
NextCure shares trade around $1.75, giving the company a market capitalization of about $25.0 million. The stock changes hands well below its 50-day moving average of $6.15 and its 200-day moving average of $8.82, while touching a 52-week low of $1.55 alongside a 52-week high of $15.74. The biotechnology firm has a beta of 1.34 and carries a current ratio of 3.47.
Inside the NextCure Pipeline
NextCure, Inc. is a clinical-stage biopharmaceutical company based in Baltimore, Maryland, focusing on the development of targeted medicines for cancer and other immune-mediated diseases. Its pipeline includes product candidates designed to address solid tumors, acute myeloid leukemia, and chronic conditions like osteoarthritis. This insider buying activity comes as the firm continues advancing its clinical candidates through early-stage trials.
What to Watch Next for NXTC
Investors will look toward upcoming corporate updates and regulatory filings to track the progress of NextCure's clinical pipeline. The company's next earnings report is anticipated around July 30, 2025, providing further insight into its financial runway and research milestones.
Related Filing Alerts
Source: John Houston's Form 4 filing on $NXTC (Jun 18, 2026). Find the original filing: NXTC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts